Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Penbutolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 0.56 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.56 |
| ▸ | HTR1A | P08908 | 5/20 | 0.89 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.89 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.89 |
| ▸ | USP2 | O75604 | 1/20 | 0.89 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.89 |
| ▸ | DRD1 | P21728 | 1/20 | 0.89 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.89 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.89 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.89 |
| ▸ | DRD3 | P35462 | 1/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.89 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Penbutolol SCHEMBL41409 | 1.00 | HTR1A (0.89) | HTR1AADRA2ASLC6A4CYP2D6ADRA1A | |
| Penbutolol SCHEMBL41407 | 1.00 | HTR1A (0.89) | HTR1AADRA2ASLC6A4CYP2D6ADRA1A | |
| Penbutolol SCHEMBL30872868 | 0.94 | HTR1A (1.00) | HTR1AADRA2ASLC6A4CYP2D6ADRA1A | |
| Penbutolol SCHEMBL31572112 | 0.94 | HTR1A (1.00) | HTR1AADRA2ASLC6A4CYP2D6ADRA1A | |
| Penbutolol SCHEMBL49358 | 0.94 | HTR1A (1.00) | HTR1AADRA2ASLC6A4CYP2D6ADRA1A | |
| Penbutolol SCHEMBL29483932 | 0.94 | HTR1A (1.00) | HTR1AADRA2ASLC6A4CYP2D6ADRA1A | |
| Penbutolol SCHEMBL41408 | 0.94 | HTR1A (1.00) | HTR1AADRA2ASLC6A4CYP2D6ADRA1A | |
| Penbutolol SCHEMBL1652319 | 0.94 | HTR1A (1.00) | HTR1AADRA2ASLC6A4CYP2D6ADRA1A | |
| Penbutolol SCHEMBL6511962 | 0.94 | HTR1A (1.00) | HTR1AADRA2ASLC6A4CYP2D6ADRA1A | |
| Penbutolol SCHEMBL7529895 | 0.93 | HTR1A (0.98) | HTR1AADRA2ASLC6A4CYP2D6ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3137 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615449-A1 | METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | Weinberg, Assa (US) | 2025-09-17 | — | — | EP | claimed |
| US-20250264469-A1 | METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER | 2025-08-21 | — | — | US | claimed |
| US-20250262195-A1 | METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | WEINBERG ASSA (US) | 2025-08-21 | — | — | US | claimed |
| EP-4598526-A1 | METHOD TO PREVENT AND TREAT GLAUCOMA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | Weinberg, Assa (US) | 2025-08-13 | — | — | EP | claimed |
| US-20250228831-A1 | METHOD TO PREVENT AND TREAT GLAUCOMA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | WEINBERG ASSA (US) | 2025-07-17 | — | — | US | claimed |
| WO-2024102328-A1 | METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | WEINBERG ASSA (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2024076697-A1 | METHOD TO PREVENT AND TREAT GLAUCOMA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | WEINBERG ASSA (US) | 2024-04-11 | — | — | WO | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| US-20240033258-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL & MECHANICAL COLLEGE (US) | 2024-02-01 | — | — | US | claimed |
| WO-2023212288-A1 | METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-02 | — | — | WO | claimed |
| EP-1479666-A1 | ESTER COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-11-24 | — | — | EP | claimed |
| US-20040229901-A1 | Method of treatment of disease using an adenosine A1 receptor antagonist | NOVACARDIA, INC. | 2004-11-18 | — | — | US | claimed |
| WO-2004075856-A2 | ADENOSINE A1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF CARDIAC AND RENAL DISEASES | NOVACARDIA, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | claimed |
| US-6429217-B1 | ADMINISTERING ACETYLCHOLINESTERASE INHIBITOR, BETA-ADRENERGIC RECEPTOR BLOCKER AND CALCIUM CHANNEL BLOCKER TO CONTROL HEARTBEAT DURING HEART SURGERY; MINIMIZES GRAFT FAILURE | EMORY UNIVERSITY | 2002-08-06 | — | — | US | claimed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |